One-two punch for cancer

Credit: CC0 Public Domain

Many cancer cells evade critical DNA surveillance and maintenance by increasing the export—by the Exportin-1 (XPO1) nucleo-cytoplasmic transport protein—of nearly all major tumor suppressor proteins from the nucleus. Thus, overexpression of XPO1 is often an indicator of poor prognosis in numerous malignancies.

Evasion of apoptosis, programmed , is another cancer hallmark. While studies of venetoclax, a potent and selective inhibitor of the anti-apoptotic protein BCL2, have revealed impressive response rates, some aggressive hematologic malignancies escape through another anti-apoptotic protein, MCL1.

Noting that both BCL2 and MCL1 expression are controlled by an XPO1-regulated protein, and that XPO1 is inactivated by SINE (selective inhibitor of nuclear export) compounds, Michael Savona, MD, and colleagues tested a combination of venetoclax and SINE compounds.

Reporting in the journal Blood Advances, they showed the combination enhanced cell killing in both in vitro and in vivo models of aggressive hematologic malignancies. Michael Byrne, DO, currently is leading a clinical trial to test this approach in patients.

Explore further

Study unveils SINE's potential of re-activating tumour fighting proteins within a cell

More information: Melissa A. Fischer et al. Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies, Blood Advances (2020). DOI: 10.1182/bloodadvances.2019000359
Citation: One-two punch for cancer (2020, March 6) retrieved 25 January 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments